Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/29261
Tüm üstveri kaydı
Dublin Core Alanı | Değer | Dil |
---|---|---|
dc.date.accessioned | 2022-10-31T06:40:25Z | - |
dc.date.available | 2022-10-31T06:40:25Z | - |
dc.date.issued | 2007-04-24 | - |
dc.identifier.citation | Hamurtekin, E. vd. (2007). "Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats". Neuroscience Letters, 420(2), 116-121. | en_US |
dc.identifier.issn | 0304-3940 | - |
dc.identifier.issn | 1872-7972 | - |
dc.identifier.uri | https://doi.org/10.1016/j.neulet.2007.04.058 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0304394007005095 | - |
dc.identifier.uri | http://hdl.handle.net/11452/29261 | - |
dc.description.abstract | Cytidine-5'-diphosphate choline (CDP-choline; citicoline) is an essential endogenous compound normally produced by the organism and is a source of cytidine and choline. Our recent studies on acute pain models demonstrate that intracerebroventricularly administered CDPcholine produces antinociception via supraspinal alpha-7 nicotinic acetylcholine receptors-mediated mechanism in rats. However, it remains to be elucidated which other supraspinal mechanisms are involved in the antinociceptive effect of CDP-choline. In this study, we investigated the role of the supraspinal opioidergic, GABAergic, alpha-adrenergic and serotonergic receptors in CDP-choline-induced antinociception. The antinociceptive effect of CDP-choline was evoked by the intracerebroventricular (i.c.v.) administration. Two different pain models were utilized: thermal paw withdrawal test and mechanical paw pressure test. The i.c.v. administration of CDP-choline (0.5, 1.0 and 2.0 mu mol) produced dose-dependent antinociception. Non-specific opioid receptor antagonist naloxone (10 mu g; i.c.v.) and GABA(B) receptor antagonist CGP-35348 (20 mu g; i.c.v.) pretreatments inhibited the antinociceptive effects of CDP-choline (1.0 mu mol; i.c.v.). In contrast, the alpha-1 adrenergic receptor antagonist prazosin (20 mu g; i.c.v.), alpha-2 adrenergic receptor antagonist yohimbine (30 mu g; i.c.v.) and non-specific scrotonin receptor antagonist methysergide (20 mu g; i.c.v.) pretreatments had no effect on CDP-choline-induced antinociception in the thermal paw withdrawal test and in the mechanical paw pressure test. Therefore, it can be postulated that i.c.v. administered CDP-choline exerts antinociceptive effect mediated by supraspinal opioid and GABAB receptors in acute pain models. Furthermore, supraspinal alpha-adrenergic and serotonergic receptors do not appear to be involved in the antinociceptive effect of CDP-choline. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Ireland | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | GABA receptors | en_US |
dc.subject | Nicotinic acetylcholine-receptors | en_US |
dc.subject | Alpha-7 nicotinic receptors | en_US |
dc.subject | Antinociception | en_US |
dc.subject | CDP-choline | en_US |
dc.subject | Opioid receptors | en_US |
dc.subject | Pain | en_US |
dc.subject | Morphine-induced antinociception | en_US |
dc.subject | Analgesic activity | en_US |
dc.subject | Agonists | en_US |
dc.subject | Release | en_US |
dc.subject | Antagonists | en_US |
dc.subject | Modulation | en_US |
dc.subject | Mechanisms | en_US |
dc.subject | Citicoline | en_US |
dc.subject | Diversity | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject.mesh | Analgesics | en_US |
dc.subject.mesh | Acute disease | en_US |
dc.subject.mesh | Adrenergic alpha-antagonists | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Efferent oathways | en_US |
dc.subject.mesh | Receptors, GABA-B | en_US |
dc.subject.mesh | Brain | en_US |
dc.subject.mesh | Cytidine diphosphate choline | en_US |
dc.subject.mesh | Disease models, animal | en_US |
dc.subject.mesh | GABA antagonists | en_US |
dc.subject.mesh | Receptors, GABA | en_US |
dc.subject.mesh | Injections,intraventricular | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Receptors,adrenergic, alpha | en_US |
dc.subject.mesh | Narcotic antagonists | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Rats, sprague-dawley | en_US |
dc.subject.mesh | Nociceptors | en_US |
dc.subject.mesh | Pain | en_US |
dc.subject.mesh | Pain measurement | en_US |
dc.subject.mesh | Pain threshold | en_US |
dc.subject.mesh | Receptors, opioid | en_US |
dc.subject.mesh | Receptors, serotonin | en_US |
dc.subject.mesh | Serotonin antagonists | en_US |
dc.title | Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000247405500005 | tr_TR |
dc.identifier.scopus | 2-s2.0-34249330701 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji ve Klinik Farmakoloji Anabilim Dalı. | tr_TR |
dc.identifier.volume | 420 | tr_TR |
dc.identifier.issue | 2 | tr_TR |
dc.relation.journal | Neuroscience Letters | en_US |
dc.contributor.buuauthor | Hamurtekin, Emre | - |
dc.contributor.buuauthor | Bağdaş, Deniz | - |
dc.contributor.buuauthor | Gürun, M. Sibel | - |
dc.contributor.researcherid | AAG-8716-2019 | tr_TR |
dc.identifier.pubmed | 17531379 | tr_TR |
dc.subject.wos | Neurosciences | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q3 | en_US |
dc.contributor.scopusid | 8717648500 | tr_TR |
dc.contributor.scopusid | 15062425700 | tr_TR |
dc.contributor.scopusid | 55664349700 | tr_TR |
dc.subject.scopus | Citicoline; Neuroprotective Agents; Glycerylphosphorylcholine | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Analgesia | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Animal model | en_US |
dc.subject.emtree | Antinociception | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Experimental model | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Serotonin antagonist | en_US |
dc.subject.emtree | Mechanical stimulation | en_US |
dc.subject.emtree | Pain | en_US |
dc.subject.emtree | Opiate antagonist | en_US |
dc.subject.emtree | Rat | en_US |
dc.subject.emtree | Methysergide | en_US |
dc.subject.emtree | 3 aminopropyl(diethoxymethyl)phosphinic acid | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Thermal stimulation | en_US |
dc.subject.emtree | Alpha adrenergic receptor | en_US |
dc.subject.emtree | Citicoline | en_US |
dc.subject.emtree | 4 aminobutyric acid B receptor | en_US |
dc.subject.emtree | 4 aminobutyric acid B receptor blocking agent | en_US |
dc.subject.emtree | 4 aminobutyric acid receptor | en_US |
dc.subject.emtree | Alpha 1 adrenergic receptor | en_US |
dc.subject.emtree | Alpha 1 adrenergic receptor blocking agent | en_US |
dc.subject.emtree | Alpha 2 adrenergic receptor | en_US |
dc.subject.emtree | Alpha 2 adrenergic receptor blocking agent | en_US |
dc.subject.emtree | Naloxone | en_US |
dc.subject.emtree | Opiate receptor | en_US |
dc.subject.emtree | Prazosin | en_US |
dc.subject.emtree | Serotonin receptor | en_US |
dc.subject.emtree | Yohimbine | en_US |
Koleksiyonlarda Görünür: | PubMed Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.